MOTS-c vs SS-31 (Elamipretide)
The two best-characterised mitochondrial peptides. They share a common interest in restoring mitochondrial function in aged tissue — but operate through fundamentally different mechanisms.
Signalling vs structural
MOTS-c is a 16-amino-acid mitochondrially-derived peptide encoded within the mitochondrial 12S rRNA gene. It is a signalling mitokine: produced by mitochondria, circulating in plasma, activating AMPK and modulating insulin sensitivity in distant tissues. It is regularly described as an endogenous exercise-mimetic.
SS-31 (elamipretide) is a synthetic aromatic-cationic tetrapeptide that accumulates in the inner mitochondrial membrane and binds cardiolipin. It is a structural stabiliser — its role is to preserve cristae architecture and respiratory-supercomplex assembly, not to act as a signal.
Evidence base and clinical status
MOTS-c is principally a research peptide. Preclinical data is robust (Lee et al. 2015, Reynolds et al. 2021), and plasma-level correlation studies in human cohorts are consistent. No phase II/III clinical trials of MOTS-c administration have been registered with major regulators.
SS-31 has progressed through phase I, II and III trials in primary mitochondrial myopathy (MMPOWER programme), dry age-related macular degeneration (ReCLAIM), and ischaemia-reperfusion contexts under Stealth BioTherapeutics. Outcomes have been mixed but the human safety dataset is unusually well characterised for a research-grade peptide.
Research positioning
MOTS-c is studied as a metabolic and exercise-mimetic signal — a probe of mitokine biology and a candidate intervention for age-related insulin resistance and sarcopenia.
SS-31 is studied as a mitochondrial architecture stabiliser — a probe of cardiolipin biology and a candidate intervention for mitochondrial-dysfunction-driven disease states.
Could they be combined?
The two compounds operate through orthogonal mechanisms — one signals, one stabilises structure — so a combined mechanistic rationale is plausible. No clinical data currently supports specific combination protocols, and the combination remains a topic for preclinical research design.